Header Logo

Connection

Stanley Xu to Immunologic Factors

This is a "connection" page, showing publications Stanley Xu has written about Immunologic Factors.
Connection Strength

2.657
  1. De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
    View in: PubMed
    Score: 0.909
  2. Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
    View in: PubMed
    Score: 0.894
  3. Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level. Neurology. 2025 May 27; 104(10):e213607.
    View in: PubMed
    Score: 0.854

© 2026 Kaiser Permanente

Your Privacy Choices